These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 31483909)
1. Drug Syntheses Beyond the Rule of 5. Tyagi M; Begnini F; Poongavanam V; Doak BC; Kihlberg J Chemistry; 2020 Jan; 26(1):49-88. PubMed ID: 31483909 [TBL] [Abstract][Full Text] [Related]
2. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Doak BC; Over B; Giordanetto F; Kihlberg J Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease. Damalanka VC; Kim Y; Galasiti Kankanamalage AC; Lushington GH; Mehzabeen N; Battaile KP; Lovell S; Chang KO; Groutas WC Eur J Med Chem; 2017 Feb; 127():41-61. PubMed ID: 28038326 [TBL] [Abstract][Full Text] [Related]
4. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry. Pillaiyar T; Namasivayam V; Manickam M Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539 [TBL] [Abstract][Full Text] [Related]
5. Macrocyclic drugs and synthetic methodologies toward macrocycles. Yu X; Sun D Molecules; 2013 May; 18(6):6230-68. PubMed ID: 23708234 [TBL] [Abstract][Full Text] [Related]
6. Cell permeability beyond the rule of 5. Matsson P; Doak BC; Over B; Kihlberg J Adv Drug Deliv Rev; 2016 Jun; 101():42-61. PubMed ID: 27067608 [TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design. Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825 [TBL] [Abstract][Full Text] [Related]
8. Macrocycles: MCR synthesis and applications in drug discovery. Abdelraheem EMM; Shaabani S; Dömling A Drug Discov Today Technol; 2018 Nov; 29():11-17. PubMed ID: 30471668 [TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Macrocyclic Drugs and Microwave-Assisted and/or Solid-Supported Synthesis of Macrocycles. Sun D Molecules; 2022 Feb; 27(3):. PubMed ID: 35164274 [TBL] [Abstract][Full Text] [Related]
10. Current Trends in Macrocyclic Drug Discovery and beyond-Ro5. Alihodžić S; Bukvić M; Elenkov IJ; Hutinec A; Koštrun S; Pešić D; Saxty G; Tomašković L; Žiher D Prog Med Chem; 2018; 57(1):113-233. PubMed ID: 29680148 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors. Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390 [TBL] [Abstract][Full Text] [Related]
12. Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. Poongavanam V; Doak BC; Kihlberg J Curr Opin Chem Biol; 2018 Jun; 44():23-29. PubMed ID: 29803972 [TBL] [Abstract][Full Text] [Related]
13. Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis. Yee NK; Farina V; Houpis IN; Haddad N; Frutos RP; Gallou F; Wang XJ; Wei X; Simpson RD; Feng X; Fuchs V; Xu Y; Tan J; Zhang L; Xu J; Smith-Keenan LL; Vitous J; Ridges MD; Spinelli EM; Johnson M; Donsbach K; Nicola T; Brenner M; Winter E; Kreye P; Samstag W J Org Chem; 2006 Sep; 71(19):7133-45. PubMed ID: 16958506 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp²-sp³ Suzuki-Miyaura coupling and ring closing metathesis. Li H; Scott JP; Chen CY; Journet M; Belyk K; Balsells J; Kosjek B; Baxter CA; Stewart GW; Wise C; Alam M; Song ZJ; Tan L Org Lett; 2015 Mar; 17(6):1533-6. PubMed ID: 25754231 [TBL] [Abstract][Full Text] [Related]
15. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease. McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594 [No Abstract] [Full Text] [Related]
16. Structural characterization of the Hepatitis C Virus NS3 protease from genotype 3a: the basis of the genotype 1b vs. 3a inhibitor potency shift. Gallo M; Bottomley MJ; Pennestri M; Eliseo T; Paci M; Koch U; Bazzo R; Summa V; Carfì A; Cicero DO Virology; 2010 Sep; 405(2):424-38. PubMed ID: 20630554 [TBL] [Abstract][Full Text] [Related]
17. Updating the portfolio of physicochemical descriptors related to permeability in the beyond the rule of 5 chemical space. Ermondi G; Vallaro M; Goetz G; Shalaeva M; Caron G Eur J Pharm Sci; 2020 Apr; 146():105274. PubMed ID: 32088315 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease. Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923 [TBL] [Abstract][Full Text] [Related]
19. Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs. Garcia Jimenez D; Vallaro M; Rossi Sebastiano M; Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G J Med Chem; 2023 Aug; 66(15):10681-10693. PubMed ID: 37490408 [TBL] [Abstract][Full Text] [Related]
20. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? Giordanetto F; Kihlberg J J Med Chem; 2014 Jan; 57(2):278-95. PubMed ID: 24044773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]